PATENT CLAIM ANALYSIS

Application Number: 16085861
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "04400R"]

Abstract:
It relates to a ribonucleic acid aptamer having an inhibitory effect on non-small cell lung cancer and a pharmaceutical composition comprising the same. The ribonucleic acid aptamer can bind to human non-small cell lung cancer in vivo or in vitro with high specificity and high affinity to achieve an effect of inhibiting non-small cell lung cancer; and the ribonucleic acid aptamer can also be linked, coupled or polymerized with other non-small cell lung cancer therapeutic drugs to achieve a more excellent effect of inhibiting non-small cell lung cancer.

Claim (Index 5):
The pharmaceutical composition according to  claim 4 , characterized in that the chemotherapeutic drug is epirubicin, and the ribonucleic acid aptamer is adducted with epirubicin to form an adduct, the molar ratio of the ribonucleic acid aptamer to the epirubicin in the adduct being 1:(2-20).

Metadata:
- Claim Count in Document: 5.0
- Percentile: 97.0
- Lexical Diversity: 1.84
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15755958', '14411176', '15500345', '13876111', '15500354']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7883399523735718
- 35 USC 102 Novelty (BERT): 0.5250700323007136
- Combined Prediction Score: 0.7620129603662861
- Mean Citation Score: 274.036032
- Max Citation Score: 299.6154
- Similarity Product: 168.15408073107002

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test